Abstract
Advanced glycation end products (AGEs) are a heterogeneous group of molecules, formed in vivo both by non-oxidative and oxidative reactions of sugars and their adducts to proteins and lipids. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGEs-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. There is a growing body of evidence that activation of RAGE (receptor for AGEs) system is also implicated in these devastating disorders. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells including hepatocytes and hepatic stellate cells. Liver is not only a target organ, but also an important site for clearance and catabolism of circulating AGEs. Although there are several papers to suggest the involvement of AGEs-RAGE system in various types of liver diseases such as non-alcoholic steatohepatitis, liver cirrhosis and cancers, as far as we know, there are few comprehensive reviews to deal with this issue. Therefore, in this paper, we shortly review the pathological role of AGEs and RAGE in various liver diseases.
Keywords: AGEs, RAGE, oxidative stress, liver disease, inflammation, fibrosis
Current Pharmaceutical Design
Title: Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Volume: 14 Issue: 10
Author(s): Hideyuki Hyogo and Sho-ichi Yamagishi
Affiliation:
Keywords: AGEs, RAGE, oxidative stress, liver disease, inflammation, fibrosis
Abstract: Advanced glycation end products (AGEs) are a heterogeneous group of molecules, formed in vivo both by non-oxidative and oxidative reactions of sugars and their adducts to proteins and lipids. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGEs-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. There is a growing body of evidence that activation of RAGE (receptor for AGEs) system is also implicated in these devastating disorders. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells including hepatocytes and hepatic stellate cells. Liver is not only a target organ, but also an important site for clearance and catabolism of circulating AGEs. Although there are several papers to suggest the involvement of AGEs-RAGE system in various types of liver diseases such as non-alcoholic steatohepatitis, liver cirrhosis and cancers, as far as we know, there are few comprehensive reviews to deal with this issue. Therefore, in this paper, we shortly review the pathological role of AGEs and RAGE in various liver diseases.
Export Options
About this article
Cite this article as:
Hyogo Hideyuki and Yamagishi Sho-ichi, Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease, Current Pharmaceutical Design 2008; 14(10) . https://dx.doi.org/10.2174/138161208784139701
DOI https://dx.doi.org/10.2174/138161208784139701 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease
Current Drug Targets Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design The Role of Selectins During Lung Inflammation and Their Potential Impact for Innovative Therapeutic Strategies
Current Respiratory Medicine Reviews Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Transcriptional Regulation of Antimicrobial Host Defense Peptides
Current Protein & Peptide Science Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Patented Techniques for the Extraction and Isolation of Secoisolariciresinol Diglucoside from Flaxseed
Recent Patents on Food, Nutrition & Agriculture Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Collagen Receptors as Potential Targets for Novel Anti-Platelet Agents
Current Pharmaceutical Design “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology